Treatment of XXXX with @entity2399 .

@entity1 @entity1165 @entity2399 @entity1166 @entity2400 @entity42245 @entity972 @entity1162 @entity1760
Twelve consecutive @entity1 who developed @entity1166 (polymorphous @entity1165 with marked @entity1162 , @entity42245 ) over a 4 year period were treated with intravenous injections of @entity2399 . In nine of the @entity1 a single bolus of 2 g completely abolished the @entity42245 within 1 to 5 min, and in three others complete abolition of the @entity42245 was achieved after a second bolus was given 5 to 15 min later. Nine of the @entity1 also received continuous infusion of @entity2400 (3 to 20 mg/min) for 7 to 48 hr until the QT interval was below 0.50 sec. In nine of the 12 @entity1 the @entity42245 was induced by antiarrhythmic agents. The QT interval preceding @entity42245 ranged from 0.54 to 0.72 sec. After the @entity2400 bolus, which prevented the recurrence of @entity42245 , no significant changes were observed in the QT interval. There were no side effects of this treatment. In eight of the 12 @entity1 @entity972 levels before the @entity42245 were below 3.5 meq/liter; @entity1760 levels were available in eight @entity1 before @entity42245 , and were normal in all. Five additional @entity1 with polymorphous @entity1165 but normal QT intervals (non- @entity42245 @entity1 ) received two to three boluses of @entity2400 . This treatment was ineffective in all, but they responded to conventional antiarrhythmic therapy. Thus, @entity2400 is a very effective and safe treatment for @entity42245 , and its application is rapid and simple. Its use is therefore recommended as the first line of therapy for @entity42245 .
